- Research article
- Open Access
Potent P2Y6 receptor mediated contractions in human cerebral arteries
BMC Pharmacologyvolume 3, Article number: 4 (2003)
Extracellular nucleotides play an important role in the regulation of vascular tone and may be involved in cerebral vasospasm after subarachnoidal haemorrhage. This study was designed to characterise the contractile P2 receptors in endothelium-denuded human cerebral and omental arteries. The isometric tension of isolated vessel segments was recorded in vitro. P2 receptor mRNA expression was examined by RT-PCR.
In human cerebral arteries, the selective P2Y6 receptor agonist, UDPβS was the most potent of all the agonists tested (pEC50 = 6.8 ± 0.7). The agonist potency; UDPβS > αβ-MeATP > UTPγS > ATPγS > ADPβS = 0, indicated the presence of contractile P2X1 P2Y2, P2Y4 and P2Y6, but not P2Y1 receptors, in human cerebral arteries. In human omental arteries, UDPβS was inactive. The agonist potency; αβ-MeATP > ATPγS = UTPγS > ADPβS = UDPβS = 0, indicated the presence of contractile P2X1, and P2Y2 receptors, but not P2Y1 or P2Y6 receptors, in human omental arteries. RT-PCR analysis of endothelium-denuded human cerebral and omental arteries demonstrated P2X1, P2Y1, P2Y2 and P2Y6 receptor mRNA expression. There were no bands for the P2Y4 receptor mRNA in the omental arteries, while barely detectable in the cerebral arteries.
P2Y6 receptors play a prominent role in mediating contraction of human cerebral arteries. Conversely, no such effect can be observed in human omental arteries and previous results confirm the absence of P2Y6 receptors in human coronary arteries. The P2Y6 receptor might be a suitable target for the treatment of cerebral vasospasm.
There is evidence of the release of adenosine triphosphate (ATP) from endothelial cells, platelets, and sympathetic nerves as well as from damaged cells in atherosclerosis, hypertension, restenosis and ischemia . Uridine triphosphate (UTP) has been shown to be released from endothelial cells in response to flow and shear stress , and it has been isolated from platelets . Since UTP is particularly present in the brain and has potent vasoconstrictor actions in human cerebral arteries, it may play a role in cerebral vasospasm after subarachnoidal haemorrhage [4–6].
Extracellular nucleotides induce vasodilatation by activating P2Y receptors on endothelial cells, while vasoconstriction is mediated by P2Y and P2X receptors on vascular smooth muscle cells. When the endothelial function is damaged in pathological conditions such as subarachnoidal haemorrhage or arteriosclerosis the vasoconstrictor actions dominate, causing cerebral vasospasm .
Recent receptor cloning has proven the existence of several different P2X and P2Y receptor subtypes, and there is evidence that five of these elicit vascular response when stimulated by extracellular nucleotides, namely P2X1, P2Y1, P2Y2, P2Y4 and P2Y6 [8, 9]. Expression of these receptors in cells has enabled characterisation of their respective pharmacological profile. P2X1 receptors have been shown by immunohistochemistry to be the dominant P2X receptor on smooth muscle cells in the vasculature [10, 11]. P2X1 receptors are activated by αβ-methylene-adenosine triphosphate (αβ-MeATP) > ATP with no effect of uridine triphosphate (UDP) or UTP . At the P2Y1 receptor adenosine 5'-O-3-thiodiphosphate (ADPβS) and adenosine diphosphate (ADP) have greater potency than ATP, while UTP and UDP are inactive [13, 14]. The P2Y2 receptor is activated with similar potencies by ATP and UTP but not by ADP or UDP; the human P2Y4 receptor is activated most potently by UTP, less potently by ATP, and not at all by nucleotide diphosphates; and the P2Y6 receptor is activated most potently by UDP but weakly by UTP, ADP and ATP .
However, the identification of P2 receptors expressed on smooth muscle cells is difficult particularly because of the absence of truly selective agonists and antagonists. Ligand instability complicates the analyses especially when performed in intact tissues as nucleotide triphosphates are rapidly metabolised by ectonucleotidases on the extracellular surface of cells . In addition, commercial nucleotides are impure. Stable nucleotides have recently started to be used in attempts to pharmacologically define the P2Y receptor subtypes. These include uridine 5'-O-thiodiphosphate (UDPβS), uridine 5'-O-3-thiotriphosphate (UTPγS), adenosine 5'-O-thiodiphosphate (ADPβS) and adenosine 5'-O-3-thiotriphosphate (ATPγS) that contain a modification of the nucleotide triphosphate group in the form of a thio substitution at the terminal phosphate, which provides stability to ectonucleotidase action. UTPγS is a potent and enzymatically stable agonist at the human P2Y2 and P2Y4 receptors, while UDPβS has recently shown to selectively activate the P2Y6 receptors [17, 18]. It is therefore now possible to discriminate between the vascular effects of different pyrimidine activated P2 receptor subtypes.
In the design of future cerebrovascular therapeutics it is important that the contractile responses of extracellular nucleotides is characterised in human subjects. This study was designed to evaluate the relative contribution of the different P2Y receptor subtypes that mediate the contractile response in human cerebral and omental arteries, which has not been done before by use of the stable pyrimidines UDPβS and UTPγS.
After endothelium removal, the vasodilatory response to acetylcholine in UTP preconstricted arteries was abolished, indicating a properly removed endothelium. Furthermore, vascular smooth muscle cell function was considered intact, since the contractile response to 60 mmol/L K+ was unaffected. P2X receptors were desensitised by addition of 10 μmol/Lαβ-MeATP. This elicited a transient contraction. After 8 min the tension was back to baseline and if αβ-MeATP was added a second time, no contraction could be observed, indicating desensitised P2X receptors.
The contractile capacity of the arteries was examined by addition of 60 mmol/L K+. For the cerebral arteries the contractile response to 60 mmol/L K+ amounted to 2.7 ± 1.3 mN above baseline tension and, for omental arteries, to 8.2 ± 0.8 mN. The nucleotide-induced contractions were thereafter calculated as percent of this K+-contraction in respective vessel segment.
Human cerebral arteries
αβ-MeATP induced potent contractions of the human cerebral arteries, indicating effects of contractile P2X receptors. After P2X receptor desensitisation (see methods), further experiments were performed to analyse P2Y receptor mediated vasoconstrictions. The endogenous nucleotides, UDP and UTP, elicited contractions of similar potencies (pEC50 = 5.5 ± 0.2 and 5.3 ± 0.2, P = n.s.). Further experiments were therefore performed using the stable nucleotide analogues UDPβS, UTPγS, ATPγS and ADPβS. Notably, the selective P2Y6 receptor agonist, UDPβS, was one log unit more potent than UDP in the human cerebral arteries (pEC50 = 6.8 ± 0.2 and 5.5 ± 0.2, P < 0.001), making it the most potent of all agonists tested. ATP and ADP induced contractions only at mmol/L concentrations. The stable purine, ATPγS, induced a considerably more potent contraction than ATP (pEC50 = 3.0 ± 0.2 for ATP and 4.8 ± 0.2 for ATPγS, P < 0.001). The ATPγS concentration-response curve resembled that of UTPγS, indicating involvement of P2Y2 receptors. On the other hand, ADPβS had no effect, indicating that there are no contractile P2Y1 receptors.
In conclusion, the potency order for the agonists in human cerebral arteries was: UDPβS > αβ-MeATP > UTPγS > ATPγS > ADPβS = 0, indicating involvement of contractile P2X1, P2Y2, P2Y4 and P2Y6, but not P2Y1 receptors, in human cerebral arteries. All data are presented in Table 1. For data concerning the endogenous nucleotides in the cerebral circulation, see Fig 1a. the stable nucleotides, see Fig 2a.
Human omental arteries
αβ-MeATP induced potent contractions of the human omental arteries, indicating effects of contractile P2X receptors. After P2X receptor desensitisation (see methods), further experiments were performed to analyse P2Y receptor mediated vasoconstrictions. The endogenous nucleotides, UTP and UDP, only induced contraction at a high concentration (mM). Conversely, the stable pyrimidines, UDPβS and UTPγS, had a markedly different pharmacological profile. Unlike the cerebral arteries, UDPβS was inactive in the human omental arteries, indicating that there are no contractile P2Y6 receptors. The potency of UTPγS was one log unit higher than that for UTP (pEC50 = 4.3 ± 0.1 and 3.3 ± 0.1, P < 0.001), indicating stability to ectonucleotidase activity. UTPγS and ATPγS induced vasoconstriction might be a result of P2Y2 or P2Y4 receptor activation in omental arteries. Like in the cerebral arteries, ADPβS did not induce vasoconstriction in the omental arteries, indicating that contractile P2Y1 receptors do not play a role.
In conclusion, the potency order for the agonists in the human omental arteries was; αβ-MeATP > ATPγS = UTPγS > ADPβS = UDPβS = 0, indicating the presence of contractile P2X1 and P2Y2 receptors, but not P2Y1 or P2Y6 receptors, in human omental arteries. All data are presented in Table 1. For data concerning the endogenous nucleotides in the cerebral circulation, see Fig 1b. the stable nucleotides, see Fig 2b.
Agarose gel electrophoresis of PCR products from endothelium-denuded, human cerebral and omental arteries demonstrated products of the expected size for the corresponding mRNA encoding human P2X1 (383 base pairs), P2Y1 (550 base pairs), P2Y2 (432 base pairs) and P2Y6 receptors (526 base pairs) (Fig. 3). There were no bands for the P2Y4 receptor mRNA (530 base pairs) in the omental arteries, while these were barely detected in the cerebral arteries. No bands were detected in controls without an RT-step.
The stable pyrimidines, UTPγS and UDPβS, were here for the first time used to characterise the P2 receptor subtypes that mediate vasoconstriction in human cerebral and omental arteries. The novel findings include that the P2Y6 receptors play a prominent role in mediating contraction of cerebral arteries. Conversely, no such effect can be observed in omental arteries and previous results confirm the absence of P2Y6 receptors in human coronary arteries . The marked effects of the P2Y6 receptor in the cerebral circulation might make it a suitable target for treatment of diseases with cerebral vasospasm.
Study of P2Y receptors has been a challenge due to the paucity of pharmacological tools for identification of receptor subtypes. Since truly selective antagonists have not yet been developed, the characterisation of P2Y receptors has mainly been performed by monitoring agonist responses. This causes difficulties, as the endogenous nucleotides UTP, UDP, ATP and ADP are neither selective nor stable. However, recent studies present the stable pyrimidines UTPγS, UDPβS as unique pharmacological tools that facilitate the characterisation of P2Y receptor subtypes in intact tissues [26, 27]. The present results clearly demonstrate the importance of stable nucleotides in the characterisation of receptors in tissue preparations with ectonucleotidase activity: In the cerebral arteries, UTP and UDP were equipotent while the stable pyrimidines demonstrated a 1.5 log unit higher potency for UDPβS as compared to UTPγS. UDP gave contractions in the omental arteries with low potency, but this could not be reproduced by UDPβS, indicating that UDP was enzymatically converted to UTP. Likewise, ADP induced contractions in both cerebral and omental arteries, which could not be reproduced by ADPβS. Thus, the endogenous nucleotides may both underestimate and overestimate the contribution of different P2Y receptor subtypes, and previous studies using non-stable nucleotides should be interpreted with caution.
Extracellular nucleotides are released from blood clots during subarachnoidal haemorrhage [28, 29]. Since both UDP and UTP are particularly present in the brain and produce sustained contraction of cerebral blood vessels, these have been postulated to contribute in the genesis of vasospasm after subarachnoidal haemorrhage [4, 6]. The present results that UTP and UDP were equipotent in inducing contraction of cerebral arteries has also been shown by others [4, 30]. Therefore, stable nucleotides were used to further characterise the pyrimidines sensitive P2Y receptors that mediated this vasoconstrictor response.
In the human cerebral arteries, UDPβS was 1.5 log units more potent than UTPγS, indicating prominent effects by the P2Y6 receptor. Interestingly, UDPβS did not act as a vasoconstrictor in human omental arteries, which is in accordance with a previous study of human coronary arteries where UDPβS also lacked an effect . It is well known that receptor distribution varies between different vascular beds in order to obtain a specific blood flow regulation. UTP has been shown to produce prominent contractions in the cerebral circulation, as compared to in the periphery . Furthermore, cerebral arteries were more sensitive to ATP than systemic arteries from the dog heart and mesentery .
The similarity in potency between ATPγS (after P2X receptor desensitisation) and UTPγS suggest the presence of contractile P2Y2 receptors in both cerebral and omental arteries. An effect by the P2Y4 receptor cannot be excluded since it is also activated by UTPγS. However, RT-PCR analysis could not detect P2Y4 mRNA expression in the omental arteries. These results indicate that the P2Y4 receptor is of none or minor importance in mediating vasoconstriction. Similar results have been reported from rat pial arteries where mRNA transcripts for the P2Y2, but not the P2Y4 receptor could be amplified .
The P2Y2 effect was less prominent than that for the P2Y6 receptors in human cerebral arteries. UTP has previously been proposed to elicit sustained vasoconstriction and vasospasm after subarachnoidal haemorrhage in cerebral arteries [4, 6]. In the present experiments, part of the UTP may have been degraded to UDP by ectonucleotidases on the extracellular surface of cells before eliciting vasoconstriction. It is therefore probable that the UTP effects seen in previous reports were really mediated by UDP sensitive P2Y6 receptors, with a lesser contribution of UTP sensitive P2Y2 receptors.
αβ-MeATP induced a transient contraction both in the human cerebral and omental arteries indicating the presence of P2X receptors. Since the P2X1 receptor is rapidly desensitised and has been shown to be the dominant subtype in cerebral vascular smooth muscle cells, these are likely to be P2X1 receptors [32, 33]. In the omental arteries, αβ-MeATP induced a transient contraction that was 2 log units more potent than that of UTPγS and ATPγS. In the cerebral circulation, the case was different. The αβ-MeATP induced contraction was 1 log unit less potent than that of UDPβS as well as 30 % less efficacious than the vasoconstriction mediated by P2Y6 and P2Y2 receptors. Thus, contractile P2Y receptors play a dominating role in the cerebral circulation, as compared to the P2X receptor effects.
The P2Y1 receptor agonist, ADPβS, had no contractile effect neither in the cerebral nor in the omental arteries. Studies in animals demonstrate that P2Y1 receptors only mediate endothelium-dependent dilatation in cerebral arteries . Furthermore, 2-MeSADP was recently shown to induce potent dilatations in preconstricted human left internal mammary artery branches, indicating an important role for endothelial P2Y1 receptors . This dilatory response was abolished after the endothelium was removed, providing evidence that there were no dilatory P2Y1 receptors in these human vascular smooth muscle cells . Likewise, when the endothelium was removed from the rat mesenteric arteries, the ADPβS induced dilatation was abolished . PCR analysis demonstrated presence of P2Y1 receptor mRNA. Although, the endothelium was functionally removed this does not necessarily mean that there are no endothelial cells and mRNA from the same, which might explain the absence of effect by ADPβS and presence of P2Y1 receptor mRNA. Also, presence of receptor mRNA does not necessarily mean there is functional receptor-protein on the cell surface.
Our results show that the selective P2Y6 receptor agonist UDPβS induce an efficacious and potent constriction of human cerebral arteries, while no such effect can be observed in human omental or coronary arteries . Conversely, mRNA for P2Y6 receptors was detected in both cerebral and omental arteries. Apparently the P2Y6 mRNA does not encode functional receptors in the omental arteries. Similar results were previously obtained in coronary arteries . Both UTP and UDP have previously proven to induce dilatation of cerebral arteries , although when vasodilatation has been studied by use of the stable pyrimidines, UTPγS and UDPβS, no dilatory effect of the P2Y6 receptor have be observed . Taken together, it is plausible that only vasoconstriction is mediated by P2Y6 receptors and that this effect is especially prominent in the cerebral circulation.
An interesting observation is the difference in potency in these experiments between the endogenous (UDP and UTP) and the stable nucleotides (UDPβS and UTPγS) and the importance of ectonucleotidases for pyrimidine degradation, as suggested by Lazarowski et al. 1997 . In cell systems, where the influence of ectonucleotidases has been minimised, UTP and UTPγS are equally potent , confirming that the increased efficacy and potency by the stable pyrimidines in the present experiments is not due to a structural change that alters the effect at the receptor.
The stable pyrimidines UTPγS and UDPβS are useful tools in the pharmacological P2 receptor characterisation in intact tissues with ectonucleotidase activity. Extracellular nucleotides stimulated contractions of human cerebral arteries primarily by activation of P2Y2, P2Y6 and P2X1 receptors, while a role for P2Y1 can be excluded. A similar pattern was seen in the omental arteries, except that no P2Y6 receptor mediated contractions was seen. These results indicate that antagonists of the P2Y6 receptor, but also the P2Y2 and P2X1 receptors may be useful in the treatment of vasospasm.
Cerebral and omental arteries were explanted during tumour surgery from 12 patients that were between 17 and 64 years of age. The cerebral arteries looked macroscopically healthy and were removed from the temporal-parietal cortex.
The cerebral and omental arteries were immediately immersed in cold oxygenated buffer solution (for composition, see below), transported to the laboratory and dissected free from adhering tissue under a microscope. The endothelium was removed from both the cerebral and omental arteries by perfusion for 5 s with 0.1% Triton X-100 followed by another 5 s of perfusion with a physiologic buffer solution (for composition, see below) using a fine needle . The vessels were then cut into cylindrical segments (1 mm long), and were immediately used in the experiments. Each cylindrical segment was mounted on two L-shaped metal prongs, one of which was connected to a force displacement transducer (FT03C) for continuous recording of the isometric tension, and the other to a displacement device . The position of the holder could be changed by means of a movable unit allowing fine adjustments of the vascular resting tension by varying the distance between the metal prongs. The mounted artery segments were immersed in temperature controlled (37°C) tissue baths containing bicarbonate based buffer solution of the following composition (mmol/L): NaCl 119, NaHCO3 15, KCl 4.6, MgCl2 1.2, NaH2PO4 1.2, CaCl2 1.5 and glucose 5.5. The solution was continuously gassed with 5% CO2 in O2 resulting in a pH of 7.4. Twelve ring segments were studied at the same time in separate tissue baths. The segments were allowed to stabilise at a resting tension of 4 mN (omental arteries) and 2 mN (cerebral arteries) for 1 h before the experiments were started. The contractile capacity of each vessel segment was examined by exposure to a potassium-rich (60 mmol/L) buffer solution in which NaCl was exchanged for an equimolar concentration of KCl (for composition, see above). When two reproducible contractions had been achieved the vessels were used for further studies.
Endothelium removal was checked by monitoring responses to acetylcholine at the end of the experiment, in arteries preconstricted by 1 mM UTP. Abolished dilatation indicated a properly removed endothelium . The range of acetylcholine-dilatation that can be observed when the endothelium is intact amounts to 30–70%, for both the human cerebral and omental arteries, depending on the quality of the endothelium after surgery (not published data). Unaffected K+ induced contractions indicated intact smooth muscle cell function. As the P2X receptors were quickly desensitised, each artery segment from both the cerebral and omental arteries was exposed to a single concentration of αβ-MeATP and the resultant responses of several segments exposed to different concentrations were added up. In this way, each artery segment was exposed to αβ-MeATP only once and the problem of tachyphylaxia was avoided. These experiments are referred to as 'single-concentration'. To study the P2Y receptor stimulated contractions without interference of simultaneous activation of P2X receptors, uridine diphosphate UDP, UDPβS, UTP, UTPγS, ADP, ADPβS, ATP and ATPγS were added after P2X receptor desensitisation with 10 μmol/L αβ-MeATP, 8 min prior to each experiment. As the P2Y receptors are only very slowly desensitised, these agonists could be added cumulatively to determine concentration-response relationships.
The experimental protocol
First 60 mM K+ was added twice to each vessel segment. Washout was performed for one hour both in between the K+ induced responses and before the experiments were started. Thereafter, one concentration of αβ-MeATP was added to each vessel segment. When the effect of this had been monitored for 3 min, 10 μmol/L of αβ-MeATP was added to all vessel segments. This was left in the tissue bath for 8 min before a P2Y receptor agonist was added in increasing concentrations. Only one P2Y receptor agonist was tested per arterial segment. Washout was performed for one hour. Thereafter, 1 mM UTP was used to preconstrict the vessel before acetylcholine was added to examine endothelium function.
The arteries were carefully dissected and the endothelium was removed (see above). The arteries were snap-frozen in liquid nitrogen immediately after acquisition and total cellular RNA was extracted using TRIzol reagent (Gibco BRL) following the supplier's instructions. The resulting RNA pellet was finally washed with 70% ice-cold ethanol, air-dried and redissolved in 10 μl diethyl-pyrocarbonate (DEPC) treated water. The RNA concentration was determined spectrophotometrically considering a ratio of OD260:280 ≥ 1.6 as pure.
RT-PCR was carried out using the GeneAmp RNA PCR kit (Perkin-Elmer, Foster City, CA, USA) on a GeneAmp PCR system 2400 (Perkin-Elmer). Specific primers for the human P2X1, P2Y1, P2Y2, P2Y4 and P2Y6 receptors were constructed based on published nucleotide sequences [21–25] (see Table 2).
First-strand cDNA synthesis carried out with the Amplitaq RNA-PCR kit (Perkin Elmer) in a 20 μl volume using random hexamers. Amplification was performed using a modified profile (2 min at 95°C followed by 30 cycles of 1 min 95°C, 1 min 55–58°C, 30 sec. 72°C and a final extension step of 7 min at 72°C). The products were separated on a 2% agarose gel containing 1.0 μg/mL ethidium-bromide and photographed. The DNA Ladder 100 bp (Promega Co.) was used as molecular weight marker. As these P2 receptors are intronless within their coding regions, PCR without the RT-step was always used to exclude genomic DNA contamination.
The project was approved by the Ethics Committee of Lund University in Sweden.
Acetylcholine, ADPβS, ATP, ATPγS, UDP, UTP and αβ-MeATP were purchased from Sigma Co. (USA). UDPβS and UTPγS were kind gifts from Inspire Pharmaceuticals, Inc. All drugs were dissolved in 0.9% saline.
Oligonucleotides were obtained from Gibco, BRL. If not stated otherwise, all reagents for the RT-PCR assay were purchased from Sigma Co. (USA).
Calculations and statistics
The negative logarithm of the drug concentration that elicited 50% contraction (pEC50) was determined by linear regression analysis using the values immediately above and below half-maximum response. Emax refers to maximum contraction calculated as percent of the contractile capacity of 60 mmol/L K+. The experiments were performed on arteries from six patients and statistical significance was accepted when P < 0.05, using Student's t-test. All differences referred to in the text have been statistically verified. Values are presented as means ± S.E.M. RT-PCR experiments were performed on three patients.
Burnstock G: Purinergic signaling and vascular cell proliferation and death. Arterioscler Thromb Vasc Biol. 2002, 22: 364-73. 10.1161/hq0302.105360.
Burnstock G: Release of vasoactive substances from endothelial cells by shear stress and purinergic mechanosensory transduction. J Anat. 1999, 194: 335-42. 10.1046/j.1469-7580.1999.19430335.x.
Ralevic V, Burnstock G: Receptors for purines and pyrimidines. Pharmacol Rev. 1998, 50: 413-92.
Shirasawa Y, White RP, Robertson JT: Mechanisms of the contractile effect induced by uridine 5-triphosphate in canine cerebral arteries. Stroke. 1983, 14: 347-55.
Keppler D, Rudigier J, Decker K: Enzymic determination of uracil nucleotides in tissues. Anal Biochem. 1970, 38: 105-14.
Urquilla PR: Prolonged contraction of isolated human and canine cerebral arteries induced by uridine 5'-triphosphate. Stroke. 1978, 9: 133-6.
Miyagi Y, Kobayashi S, Nishimura J, Fukui M, Kanaide H: Dual regulation of cerebrovascular tone by UTP: P2U receptor-mediated contraction and endothelium-dependent relaxation. Br J Pharmacol. 1996, 118: 847-56.
Evans RJ, Surprenant A, North RA: P2X receptors. In: The P2 nucleotide receptors. Edited by: Turner JT, Weisman GA, Fedan JS. 1998, Totowa, NJ: Human Press Inc, 109-134.
Harden TK, Nicholas RA, Schlater JB, Lazarowski ER, Boyer JL: Pharmacological selectivities of molecularly defined subtypes of P2Y receptors. In: The P2 nucleotide receptors. Edited by: Turner JT, Weisman GA, Fedan JS. 1998, Totowa, NJ: Human Press Inc, 109-134.
Hansen MA, Dutton JL, Balcar VJ, Barden JA, Bennett MR: P2X (purinergic) receptor distributions in rat blood vessels. J Auton Nerv Syst. 1999, 75: 147-55. 10.1016/S0165-1838(98)00189-1.
Lewis CJ, Evans RJ: Comparison of P2X receptors in rat mesenteric, basilar and septal (coronary) arteries. J Auton Nerv Syst. 2000, 81: 69-74. 10.1016/S0165-1838(00)00117-X.
Valera S, Hussy N, Evans RJ, Adami N, North RA, Surprenant A, Buell G: A new class of ligand-gated ion channel defined by P2x receptor for extracellular ATP. Nature. 1994, 371: 516-9. 10.1038/371516a0.
Léon C, Hechler B, Vial C, Leray C, Cazenave JP, Gachet C: The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Lett. 1997, 403: 26-30. 10.1016/S0014-5793(97)00022-7.
Palmer RK, Boyer JL, Schachter JB, Nicholas RA, Harden TK: Agonist action of adenosine triphosphates at the human P2Y1 receptor. Mol Pharmacol. 1998, 54: 1118-23.
Nicholas RA, Watt WC, Lazarowski ER, Li Q, Harden K: Uridine nucleotide selectivity of three phospholipase C-activating P2 receptors: identification of a UDP-selective, a UTP-selective, and an ATP- and UTP-specific receptor. Mol Pharmacol. 1996, 50: 224-9.
Gordon JL: Extracellular ATP: effects, sources and fate. Biochem J. 1986, 233: 309-19.
Hou M, Harden TK, Kuhn CM, Baldetorp B, Lazarowski E, Pendergast W, Moller S, Edvinsson L, Erlinge D: UDP acts as a growth factor for vascular smooth muscle cells by activation of P2Y(6) receptors. Am J Physiol Heart Circ Physiol. 2002, 282: H784-92.
Lazarowski ER, Watt WC, Stutts MJ, Brown HA, Boucher RC, Harden TK: Enzymatic synthesis of UTP gamma S, a potent hydrolysis resistant agonist of P2U-purinoceptors. Br J Pharmacol. 1996, 117: 203-9.
Hamel E, Assumel-Lurdin C, Edvinsson L, Fage D, MacKenzie ET: Neuronal versus endothelial origin of vasoactive acetylcholine in pial vessels. Brain Res. 1987, 420: 391-6. 10.1016/0006-8993(87)91263-7.
Högestatt ED, Andersson KE, Edvinsson L: Mechanical properties of rat cerebral arteries as studied by a sensitive device for recording of mechanical activity in isolated small blood vessels. Acta Physiol Scand. 1983, 117: 49-61.
Communi D, Pirotton S, Parmentier M, Boeynaems JM: Cloning and functional expression of a human uridine nucleotide receptor. J Biol Chem. 1995, 270: 30849-52. 10.1074/jbc.270.52.30849.
Communi D, Parmentier M, Boeynaems JM: Cloning, functional expression and tissue distribution of the human P2Y6 receptor. Biochem Biophys Res Commun. 1996, 222: 303-8. 10.1006/bbrc.1996.0739.
Parr CE, Sullivan DM, Paradiso AM, Lazarowski ER, Burch LH, Olsen JC, Erb L, Weisman GA, Boucher RC, Turner JT: Cloning and expression of a human P2U nucleotide receptor, a target for cystic fibrosis pharmacotherapy. Proc Natl Acad Sci U S A. 1994, 91: 3275-9.
Valera S, Talabot F, Evans RJ, Gos A, Antonarakis SE, Morris MA, Buell GN: Characterization and chromosomal localization of a human P2X receptor from the urinary bladder. Receptors Channels. 1995, 3: 283-9.
Léon C, Vial C, Cazenave JP, Gachet C: Cloning and sequencing of a human cDNA encoding endothelial P2Y1 purinoceptor. Gene. 1996, 171: 295-7. 10.1016/0378-1119(96)00027-3.
Malmsjö M, Hou M, Harden TK, Pendergast W, Pantev E, Edvinsson L, Erlinge D: Characterization of contractile P2 receptors in human coronary arteries by use of the stable pyrimidines uridine 5'-O-thiodiphosphate and uridine 5'-O-3-thiotriphosphate. J Pharmacol Exp Ther. 2000, 293: 755-60.
Malmsjö M, Adner M, Harden TK, Pendergast W, Edvinsson L, Erlinge D: The stable pyrimidines UDPbetaS and UTPgammaS discriminate between the P2 receptors that mediate vascular contraction and relaxation of the rat mesenteric artery. Br J Pharmacol. 2000, 131: 51-6.
Shirahase H, Usui H, Manabe K, Kurahashi K, Fujiwara M: Endothelium-dependent contraction and -independent relaxation induced by adenine nucleotides and nucleoside in the canine basilar artery. J Pharmacol Exp Ther. 1988, 247: 1152-7.
Sima B, Macdonald L, Marton LS, Weir B, Zhang J: Effect of P2-purinoceptor antagonists on hemolysate-induced and adenosine 5'-triphosphate-induced contractions of dog basilar artery in vitro. Neurosurgery. 1996, 39: 815-21.
Sima B, Weir BK, Macdonald RL, Zhang H: Extracellular nucleotide-induced [Ca2+]i elevation in rat basilar smooth muscle cells. Stroke. 1997, 28: 2053-8.
Toda N, Okunishi H, Taniyama K, Miyazaki M: Responses to adenine nucleotides and related compounds of isolated dog cerebral, coronary and mesenteric arteries. Blood Vessels. 1982, 19: 226-36.
Lewis CJ, Ennion SJ, Evans RJ: P2 purinoceptor-mediated control of rat cerebral (pial) microvasculature; contribution of P2X and P2Y receptors. J Physiol. 2000, 527 (Pt 2): 315-24.
Bo X, Karoon P, Nori SL, Bardini M, Burnstock G: P2X purinoceptors in postmortem human cerebral arteries. J Cardiovasc Pharmacol. 1998, 31: 794-9. 10.1097/00005344-199805000-00020.
Wihlborg A-K, Malmsjö M, Eyjolfsson A, Gustafsson R, Jacobson K, Erlinge D: Extracellular nucleotides induce vasodilatation in human arteries via prostaglandin, nitric oxide and endothelium-dependent hyperpolarizing factor. Br J Pharmacol.
Hardebo JE, Kahrstrom J, Owman C, Salford LG: Endothelium-dependent relaxation by uridine tri- and diphosphate in isolated human pial vessels. Blood Vessels. 1987, 24: 150-5.
Lazarowski ER, Homolya L, Boucher RC, Harden TK: Identification of an ecto-nucleoside diphosphokinase and its contribution to interconversion of P2 receptor agonists. J Biol Chem. 1997, 272: 20402-7. 10.1074/jbc.272.33.20402.
This study has been supported by the Swedish Hypertension Society, the Royal Physiographic Society (Lund), The Swedish Migraine Society, the Heart and Lung Foundation, the Swedish Medical Association and The Swedish Medical Research Council Grant X0667 and 5958. The authors wish to thank Inspire Pharmaceuticals Inc. for supplying us with UDPβS and UTPγS.
Malin Malmsjö: Designed the study and performed the pharmacological experiments and wrote the manuscript.
Mingyan Hou: Performed the RT-PCR experiments.
William Pendergast: Supplied the stable pyrimidines and proof-read the manuscript.
David Erlinge: Conceived the study and participated in writing the manuscript.
Lars Edvinsson: Guided throughout the study and participated in writing the manuscript.